Methods for diagnosing and treating pediatric neoplasms

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007210, C435S007230, C530S387100, C530S387700

Reexamination Certificate

active

07816089

ABSTRACT:
The present invention provides a method for determining whether a subject has a pediatric neoplasm. The present invention further provides a method for assessing the efficacy of therapy to treat a pediatric neoplasm in a subject who has undergone or is undergoing treatment for a pediatric neoplasm. In addition, the present invention provides a method for assessing the prognosis of a subject who has a pediatric neoplasm. Finally, the present invention provides a method for treating a pediatric neoplasm in a subject in need of treatment thereof.

REFERENCES:
patent: 5527897 (1996-06-01), Oda et al.
patent: 6127178 (2000-10-01), Israel et al.
patent: 2002/0151681 (2002-10-01), Rosen et al.
Sablitzky et al. (Cell Growth & Differentiation, Dec. 1998, 9:1015-1024).
Renné et al. (Am J. Pathol. 2006, 169: 655-664).
Boyd (The Basic Science of Oncology, 1992, McGraw-Hill, Inc., p. 379).
Taber's Cyclopedic Medical Dictionary (1985, F.A. Davis Company, Philadelphia, p. 274).
Busken, C. et al, (Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850).
Kaiser (Science, 2006, 313, p. 1370).
Bowie et al (Science, 1990, 257:1306-1310).
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).
Sambrook et al. (Molecular Cloning: A Laboratory Manual, 1989, p. 18.70-18.75).
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).
Rudikoff et al, (PNAS, USA, 1982, 79: 1979-1983).
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).
Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444).
Biedler et al. (Cancer Research, Nov. 1973, 33:2643-2652).
Stupack et al. (Nature, Jan. 2006, vol. 439: 95-99).
Ren, C et al, (1998, Cancer Res., 58(6): 1285-90).
Gingrich, JR et al. (1996, Cancer Res., 56(18): 4096-4102).
Gebauer et al. (Genes, Chromosomes, & Cancer, 2004, 41: 297-308).
Sato et al. (European J. Surgical Oncol. 2003 29:284-287).
Alaminos et al. (Pediatr. Blood Cancer 2005 : 45:909-915).
Burchill SA et al., “Circulating Neuroblastoma Cells Detected by Reverse Transcriptase Polymerase Chain Reaction for Tyrosine Hydroxylase mRNA Are an Independent Poor Prognostic Indicator in Stage 4 Neuroblastoma in Children Over 1 Year,” J Clin Oncol. Mar. 15, 2001; 19(6):1795-1801.
Cotta CV et al., “The Helix-Loop-Helix Protein Id2 is Expressed Differentially and Induced by Myc in T-Cell Lymphomas,” Cancer, Feb. 1, 2008; 112(3):552-61.
Fukuma, M. et al., “Upregulation of Id2, An Oncogenic Helix-Loop-Helix Protein, Is Mediated by the Chimeric EWS/ets Protein in Ewing Sarcoma,” Oncogene (2003) 22, 1-9.
A. Lasorella et al., “Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in Rb Mutant Mice,” Molecular and Cellular Biology, May 2005, vol. 25, No. 9, pp. 3563-3574.
A. Lasorella et al., “Id2 is a Retinoblastoma Protein Target and Mediates Signalling by Myc Oncoproteins,” Nature, Oct. 5, 2000; 407 (6804):592-8.
Nishimori, H. et al., “The Id2 Gene Is a Novel Target of Transcriptional Activation by EWS-ETS Fusion Proteins in Ewing Family Tumors,” Oncogene (2002) 21, 8302-8309.
Renne, C. et al., “Aberrant Expression of ID2, a Suppressor of B-Cell-Specific Gene Expression, in Hodgkin's Lymphoma,” The American Journal of Pathology, vol. 169, No. 2, Aug. 2006, 655-664.
Vandeputte DA et al, “Expression and Distribution of Id Helix-Loop-Helix Proteins in Human Astrocytic Tumors,” Glia, Jun. 2002; 38(4):329-38.
Cheung, Irene Y. et al., Molecular Detection of GAGE Expression in Peripheral Blood and Bone Marrow: Utility as a Tumor Marker for Neuroblastoma, Clinical Cancer Research, vol. 3, pp. 821-826, May 1997.
Corrias, Maria Valeria et al., Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques: Accuracy and Relationship with Clinical Features of Patients, Clinical Cancer Research, vol. 10, pp. 7978-7985, Dec. 1, 2004.
Alevizopoulos et al., Cyclin E and c-Myc Promote Cell Proliferation in the Presence of p16INK4a and of Hypophosphorylated Retinoblastoma Family Proteins,EMBO J., 16:5322-33, 1997.
Biggs et al., A Human Id-Like Helix-Loop-Helix Protein Expressed During Early Development,Proc. Natl. Acad. Sci. USA, 89:1512-16, 1992.
Bordow et al., Prognostic Significance of MYCN Oncogene Expression in Childhood Neuroblastoma,J. Clin. Oncol., 16:3286-94, 1998.
Boyd et al., c-Myc target gene specificity is determined by a post-DNA-binding mechanism. Proc. Natl Acad. Sci. USA, 95:13887-92, 1998.
Brodeur et al., Neuroblastoma, Effect of Genetic Factors on Prognosis and Treatment,Cancer, 70:1685-94, 1992.
Cance et al., Altered Exprssion of the Retinoblastoma Gene Product in Human Sarcomas,N. Engl. J. Med., 323:1457-62, 1990.
Chan et al., MYCN Protein Expression As a Predictor of Neuroblastoma Prognosis,Clin. Cancer Res., 3:1699-706, 1997.
Clarke et al., Requirement For a Functional Rb-1 Gene in Murine Development,Nature, 359:328-30, 1992.
Cohn et al., MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN,J. Clin. Oncol., 18:3604-13, 2000.
Cooper et al., Expression of the Id Family Helix-Loop-Helix Regulators During Growth and Development in the Hematopoietic System,Blood, 89:3155-65, 1997.
Cordon-Cardo et al., Altered Expression of the Retinoblastoma Gene Product: Prognostic Indicator in Bladder Cancer,J. Natl. Cancer Inst., 84:1251-56, 1992.
Dyson, N., The regulation of E2F by pRB-family proteins. Genes & Dev., 12:2245-62, 1998.
Florio et al., Id2 Promotes Apoptosis By a Novel Mechanism Independent of Dimerization to Basic Helix-Loop-Helix Factors,Mol. Cell. Biol., 18:5435-44, 1998.
Goodrich and Lee, Abrogation by c-Myc of G1 Phase Arrest Induced By RB Protein But Not By p53 [published erratum:Nature, 360:491, 1992].
Hirning et al., A Comparative Analysis of N-myc and C-myc Expression and Cellular Proliferation in Mouse Organogenesis,Mech. Dev., 33:119-25, 1991.
Hiyama et al., Immunohistochemical Analysis of N-myc Protein Expression in Neuroblastoma: Correlation With Prognosis of Patients,J. Pediatr. Surg., 26:838-43, 1991.
Iavarone et al., The Helix-Loop-Helix Protein Id-2 Enhances Cell Proliferation and Binds to the Retinoblastoma Protein,Genes Dev., 8:1270-84, 1994.
Iavarone and Massague, E2F and histone deacetylase mediate transforming growth factor beta repression of cdc25A during keratinocyte cell cycle arrest. Mol. Cell. Biol., 19:916-22, 1999.
Ishiguro et al., Expression of ID2 and ID3 mRNA in Human Lymphocytes,Leuk. Res., 19(12):989-96, 1995.
Ishiguro et al., Id2 Expression Increases With Differentiation of Human Myeloid Cells,Blood, 78(12):5225-31, 1996.
Jacks et al., Effects of an Rb Mutation in the Mouse,Nature, 359:295-300, 1992.
Jen et al., Expression patterns of Id1, Id2, and Id3 are highly related but distinct from that of Id4 during mouse embryogenesis. Dev. Dyn., 207:235-52, 1996.
Jen et al., Each Member of the Id Gene Family Exhibits a Unique Expression Pattern in Mouse Gastrulation and Neurogenesis,Dev. Dyn., 208:92-106, 1997.
Kibel, AS et al (2000, J Urol, 164(1):192-6).
Kleef et al., The Helix-Loop-Helix Protein Id2 Is Overexpressed in Human Pancreatic Cancer,Cancer Res., 58(17):3769-72, 1998.
Kratzke et al., Rb and p16INK4a Expression in Resected Non-Small Cell Lung Tumors,Cancer Res., 56:3415-20, 1996.
Lasorella et al., ID2 Specifically Alters Regulation of the Cell Cycle by Tumor Suppressor Proteins,Mol. Cell. Biol., 16:2570-78, 1996.
Lasorella et al., Id2 Is a Retinoblastoma Protein Target and Mediates Signalling by Myc Oncoproteins,Nature, 407:592-98, 2000.
Lasorella et al (Cancer Research, 2002, 62:301-305).
Lee et al., Mice Deficient for Rb Are Nonviable and Show Defects in Neurogenesis and Hematopoiesis,Nature, 359:288-94, 1992.
Lee et al., Dual Roles of the Retinoblastoma Protein in Cell Cycle Regulation and Neuron Differentiation,Genes Dev., 8:2008-21, 1994.
Lyden et al., Id1 and Id3 Are Required For Neurogenesis, Angiogenesis and Vascularization of Tumour Xenografts,Nature, 401:670-77, 1999.
Maris and Matthay, Mol

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods for diagnosing and treating pediatric neoplasms does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing and treating pediatric neoplasms, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing and treating pediatric neoplasms will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4222758

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.